reports
Medigene Files Patent for Unique NK-Specific TCR Construct with Europe...
Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the submission of a patent for a novel natural killer (NK) cell-specific TCR construct to the European Patent Office. With that, Medigene is advancing its TCR-guided strategy by expanding the application of its proprietary 3S (sensitive, specific, and safe) TCRs into NK cells. This patent application marks a majo...
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partne...
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers Planegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors. The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S ...
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Te...
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S. Planegg/Martinsried, February 19, 2025. (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by the U.S. Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. The U.S. patent for the JOVI technology was granted at the end of last year with the offi...
Medigene AG announces closing of its first SEPA tranche
Medigene AG announces closing of its first SEPA tranche Planegg/Martinsried, February 3, 2025. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced the closing of its first tranche of the Standby Equity Purchase Agreement (“SEPA”) with a fund managed by Yorkville Advisors Global, LP (“Yorkville”) announced on January 24, 2024. The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average pric...
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell ...
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers Planegg/Martinsried, December 9, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the co-development of T cell receptor-guided T cell engagers (TCR-TCEs) with WuXi Biologics. The selection of this first target is a key...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, In...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially best-in-class TCRs Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million milestone payment from Regenero...
Medigene AG Announces Refocus of Corporate Strategy and Organizational...
Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment Planegg/Martinsried, November 26, 2024. (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today an update of its corporate strategy to refocus its capital allocation on R&D programs with highest potential for return on invested capital resulting in an organizational realignment. This strategic refocus supports the Company’s short-, mid-, and long-term vision of generatin...
Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at ...
Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024 Planegg/Martinsried, November 12, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented data on the newest addition to its End-to-End (E2E) Platform, an Interferon-Gamma (IFN-γ) Biosensor technology that allows real-time monitoring and quantification of IFN-γ release from cytokine-secreting cells at the Society of Immunotherapy of Cancer (SITC) 2024 Confer...
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS a...
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024 Planegg/Martinsried, November 11, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented latest updates on its End-to-End (E2E) Platform technology - the UniTope and TraCR technology, a universal detection system for tagging and tracking recombinant TCRs (rTCRs), at the Protein & Antibody Engineering Summit (PEGS) in Barcelona from November 5-7, 2024, an...
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors...
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024 Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars highlighted Medigene’s proprietary End-to-End Platform for generation of extraordinary T cell receptors for application in various modalities and overview of the lead TCR-T therapy program MDG1015 Planegg/Martinsried, November 8, 2024. (Medigene or the “Company”, FSE: MDG1, Prime St...
Medigene to Present at Upcoming Investor Conferences
Medigene to Present at Upcoming Investor Conferences Planegg/Martinsried, October 29, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will attend BIO-Europe from November 4-6, 2024 in Stockholm as well as at the Investival Showcase Biotech, Heathcare, Medtech conference on November 18, 2024 in London. In addition, the Company will present at the Deutsches Eigenkapitalforum from November 25-27, 2024 in Frankfurt. BIO-Europe 2024Locat...
Medigene AG reports Financial Results and Business Update for Q3 2024
Medigene AG reports Financial Results and Business Update for Q3 2024 Planegg/Martinsried, October 24, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today reported financial results and provided a business update for the third quarter ended September 30, 2024. The Quarterly Statement Q3 2024 can be found on the website: . "During the third quarter of 2024, our focus remained on executing our strategic plan and creating additional value...
Medigene presents UniTope and TraCR a universal detection system for 3...
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024 Planegg/Martinsried, October 17, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented a universal detection system for 3S (specific, sensitive, and safe) recombinant TCRs (rTCRs), UniTope & TraCR, at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. The presented ...
Medigene to Present at Upcoming Scientific Conferences
Medigene to Present at Upcoming Scientific Conferences Planegg/Martinsried, October 16, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present at the 16th Annual Protein & Antibody Engineering Summit (PEGS) to be held from November 5-7, 2024 in Barcelona as well as at the Cell 2024 conference by Oxford Global from November 6-8, 2024 in London. In addition, two posters will be presented at the 39th Society for Immunotherapy of Cancer...
Medigene will Present at ASGCT 2024 and Host R&D Event
Medigene will Present at ASGCT 2024 and Host R&D Event Planegg/Martinsried, October 2, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present a poster at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. In addition, the Company will host an R&D Event on Medigene’s optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, Oct...
Medigene AG Expands Protection of its KRAS Library with Filing of New ...
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021 Planegg/Martinsried, September 25, 2024 – (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the filing of a new patent application protecting MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11, for the TCR-T ...
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for ...
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies Planegg/Martinsried, September 16, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will host an R&D Event on Medigene’s optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, October 10, 2024, at 4.30 pm CET / 10:30 am ET. A live Q&A session will follow the formal presentations and discu...
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, ...
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications Planegg/Martinsried, September 5, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its lead program MDG1015 for the ...
Medigene AG Secures Two Additional Patents for Technologies in Its End...
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform Planegg/Martinsried, August 29, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced that the Company has been issued a patent by the European Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. In addition, a further patent has been granted by the Hong Kong Patent O...
Medigene to Present at Upcoming Investor Conferences
Medigene to Present at Upcoming Investor Conferences Planegg/Martinsried, August 28, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will be presenting at the the annual German Fall Conference to be held in Frankfurt from September 2-3, 2024 as well as at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York and at the Baader Investment Conference from September 23-26, 2024 in Munich. Corp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.